A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma

Annals of Oncology

Volumn 20, Issue 11, 2009, Pages 1787-1793

  Ang, J E ^a   Shah, R N ^a   Everard, M ^a   Keyzor, C ^a   Coombes, I ^a   Jenkins, A ^b   Thomas, K ^a   A'Hern, R ^a   Jones, R L ^a   Blake, P ^a   Gabra, H ^c   Hall, G ^b   Gore, M E ^a   Kaye, Stan B ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Carboplatin; Carcinosarcoma; Doxorubicin; Endometrial carcinoma; Paclitaxel; Sequential chemotherapy

Indexed keywords

ANTIBIOTIC AGENT; CARBOPLATIN; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CARCINOSARCOMA; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; ENDOMETRIUM CARCINOMA; FATIGUE; FEASIBILITY STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PANCYTOPENIA; PARESTHESIA; PERCEPTION DEAFNESS; PHARYNGITIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SIDE EFFECT; SKIN DISEASE; STOMATITIS; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION;

EID: 71049186346     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp193     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106.
2. Markman M. Hormonal therapy of endometrial cancer. Eur J Cancer 2005; 41: 673.
3. Van Wijk FH, Lhomme C, Bolis G et al. Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group. Eur J Cancer 2003; 39: 78.
4. Moore TD, Phillips PH, Nerenstone SR, Cheson BD. Systemic treatment of advanced and recurrent endometrial carcinoma: Current status and future directions. J Clin Oncol 1991; 9: 1071.
5. Wadler S, Levy DE, Lincoln ST et al. Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93. J Clin Oncol 2003; 21: 2110.
6. Aapro MS, van Mijk FH, Bolis G et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: Definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 2003; 14: 441-448.
7. Thigpen JT, Brady MF, Homesley HD et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: A gynaecologic oncology group study. J Clin Oncol 2004; 22: 3902.
8. Fleming GF, Brunetto VL, Cella D et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol 2004; 22(11): 2159-2166.
9. Chang J, Sharpe JC, A'Hern RP et al. Carcinosarcoma of the ovary: incidence, prognosis, treatment and survival of patients. Ann Oncol 1995; 6: 755-758.
10. Mano MS, Rosa DD, Azambuja E et al. Current management of ovarian carcinosarcoma. Int J Gynecol Cancer 2007; 17: 316-324.
11. du Bois A, Pfisterer J, Burchardi N et al. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynaecologic malignancies: A prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut). Gynecol Oncol 2007; 107: 518-525.
12. Sutton G, Brunetto VL, Kilgore L et al. A phase III trial of ifosphamide with or without cisplatin in carcinosarcoma of the uterus: A Gynaecologic Oncology Group Study. Gynecol Oncol 2000; 79: 147-153.
13. Homesley HD, Filiaci VL, Bitterman P et al. Phase III trial of ifosphamide versus ifosphamide plus paclitaxel as first line treatment of advanced or recurrent uterine carcinosarcoma (mixed mesodermal tumours): A Gynecologic Oncology Group Study. Gynecol Oncol 2006; 101: 531 (Abstr 101).
14. Gregory RK, Hill ME, Moore J et al. Combining platinum, paclitaxel and anthracycline in patients with advanced gynaecological malignancy. Eur J Cancer 2000; 36(4): 503-507.
15. Gibbs DD, Pyle L, Allen M et al. A phase I dose-finding study of a combination of pegylated liposomal doxorubicin (Doxil), carboplatin and paclitaxel in ovarian cancer. Br J Cancer 2002; 86(9): 1379-1384.
16. Hess V, Verrill MW, Bomphray CC et al. Phase 1 study of carboplatin, doxorubicin and weekly paclitaxel in patients with advanced ovarian carcinoma. Ann Oncol 2003; 14: 638-642.
17. Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979; 63(11-12): 1727-1733.
18. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748-1756.
19. Pectasides D, Xiros N, Papaxoinis G et al. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. Gynecol Oncol 2008; 109: 250-254.
20. Fleming GF, Filiaci VL, Bentley RC et al. Phase III randomised trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: A Gynaecologic Oncology Group Study. Ann Oncol 2004; 15: 1173-1178.
21. Fleming GF. Systemic chemotherapy for uterine carcinoma: Metastatic and adjuvant. J Clin Oncol 2007; 25(20): 2983-2990.
22. Oza AM, Elit L, Provencher D et al. A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b. J Clin Oncol 2008; 26(15S): 5516.
23. Slomovitz BM, Lu KH, Johnston T et al. A phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC). J Clin Oncol 2008; 26(15S): 5502.
24. Wright JD, Powell MA, Rader JS et al. Bevacizumab therapy in patients with recurrent uterine neoplasms. Anticancer Res 2007; 5B: 3525-3528.
25. Nimeiri HS, Oza AM, Morgan RJ et al. Sorafenib (SOR) in patients (pts) with advanced/recurrent uterine carcinoma (UCA) or carcinosarcoma (CS): a phase II trial of the University of Chicago, PMH, and California Phase II Consortia. J Clin Oncol 2008; 26(15S): 5585.
26. Oza AM, Eisenhauer EA, Elit L et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol 2008; 26(26): 4319-4325.